肌萎缩侧索硬化症 (ALS) 市场分析及预测（至 2035 年）：按类型、产品、服务、技术、组件、应用、设备、流程和最终用户划分

肌萎缩侧索硬化症 (ALS) 市场预计将从 2024 年的 12 亿美元成长到 2034 年的 21 亿美元，复合年增长率约为 5.8%。 ALS 市场涵盖用于治疗 ALS（进行性神经退化性疾病）的药物、诊断和支持疗法。基因疗法的进步、新药研发以及研究经费的增加是推动该市场成长的主要因素。人们对 ALS 的认识不断提高以及诊断技术的进步正在推动对创新治疗方法的需求。策略联盟和监管支援进一步加速了市场成长，其重点在于延长患者寿命和提高患者生活品质。

肌萎缩侧索硬化症 (ALS) 市场正经历着蓬勃发展，这主要得益于治疗方案的进步和诊断技术的创新。其中，治疗领域成长最为迅猛，主要由疾病修正治疗疗法和对症疗法推动。创新药物配方和新型治疗方法方案的出现，进一步促进了该领域的扩张。诊断领域成长排名第二，主要得益于生物标记技术和基因检测技术的显着进步。这些创新正在加强早期诊断和个人化治疗方案的实施。研发活动也不断加强，并着重于神经保护剂和再生医学。新兴生物技术和基因疗法备受瞩目，并有望彻底改变 ALS 的治疗模式。人工智慧在药物研发和病患管理的应用，进一步提升了市场成长前景。製药公司与研究机构之间的合作正在促进创新，并加速有效解决方案的发展。公众对 ALS 的认知和教育程度的提高，也推动了对先进医疗保健解决方案的需求成长。

市场概况：

肌萎缩侧索硬化症 (ALS) 市场正经历动态变化，主要企业占据显着的市场份额。定价策略不断演变以应对竞争压力和患者需求，从而催生出创新的定价模式。生物技术的进步和对疾病机制更深入的理解正推动新产品的上市，进而促进市场发展。这些进展在拓展治疗选择、改善病患预后的同时，也加剧了市场竞争。竞争基准研究揭示了主要企业之间的激烈竞争，而策略联盟和合作研究正在塑造市场动态。监管的影响至关重要，北美和欧洲的监管机构制定了严格的指导方针，对市场准入和扩大策略产生影响。 ALS 市场的特点是研发投入巨大，主要集中在新型治疗方法和个人化医疗方面。专利到期和非专利处方药的上市进一步加剧了市场的复杂性，预计将改变竞争格局，并推动市场发展。

主要趋势和驱动因素：

在研发进步的推动下，肌萎缩侧索硬化症 (ALS) 市场持续发展。神经系统研究经费的增加正在加速创新治疗方法的发现。新药认证和临床试验的扩展正在拓宽治疗选择，并满足 ALS 治疗领域尚未满足的需求。个人化医疗的兴起是一大趋势，基因检测使得针对个别患者特征的标靶治疗成为可能。这种方法提高了治疗效果和患者预后。製药公司与研究机构之间的合作正在加速创新步伐。包括远端医疗和远距监测在内的数位健康技术正在改变患者管理方式，并改善医疗服务的可近性。这些技术能够实现即时数据收集，从而加强疾病追踪和介入策略。对孤儿药研发的监管支持和奖励正在创造一个有利于市场成长的环境。随着相关人员利用这些趋势推动诊断、治疗和患者照护方面的进步，ALS 市场有望进一步扩张。

压制与挑战：

肌萎缩侧索硬化症 (ALS) 市场面临许多重大限制和挑战。其中一个主要限制因素是药物研发和临床试验的高成本。这种经济负担限制了新进入者，并减缓了创新步伐。此外，ALS 的罕见性限制了符合临床研究条件的患者数量，导致受试者招募困难，并延长了研究週期。另一个挑战是缺乏确诊检测方法。这会延误诊断和治疗启动，影响患者的预后。 ALS 病理的复杂性也阻碍了有效治疗方法的发展。研究人员在理解疾病的潜在机制方面面临许多困难。此外，监管障碍和新治疗方法严格的核准流程也会延缓其上市。同时，亟需加强医疗专业人员和民众的认知和教育。这种知识差距可能会阻碍早期诊断和干预，进而影响整体市场成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

• 宏观经济分析
• 市场趋势
• 市场驱动因素
• 市场机会
• 市场限制因素
• 复合年均成长率：成长分析
• 影响分析
• 新兴市场
• 技术蓝图
• 战略框架

第四章：细分市场分析

• 市场规模及预测：依类型
  • 散发性肌萎缩性侧索硬化症
  • 遗传性肌萎缩性侧索硬化症
• 市场规模及预测：依产品划分
  • Riluzole
  • Edaravone
  • 提拉塞姆奇布
  • 纽德克斯特
  • 马西替尼
• 市场规模及预测：依服务划分
  • 病人支援服务
  • 咨询服务
  • 临床试验服务
• 市场规模及预测：依技术划分
  • 生物技术
  • 药理基因体学
  • 基因治疗
  • 干细胞疗法
• 市场规模及预测：依组件划分
  • 活性成分
  • 添加剂
• 市场规模及预测：依应用领域划分
  • 医院
  • 门诊手术中心
  • 研究机构
• 市场规模及预测：依设备划分
  • 非侵入性通气
  • 经皮视镜胃造瘻术
• 市场规模及预测：依製程划分
  • 药物研发
  • 临床试验
  • 获得监管机构的核准
  • 商业化
• 市场规模及预测：依最终用户划分
  • 医疗保健提供者
  • 病人
  • 製药公司

第五章 区域分析

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲
• 亚太地区
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲
  • 台湾
  • 亚太其他地区
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 义大利
  • 其他欧洲国家
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非
  • 撒哈拉以南非洲
  • 其他中东和非洲地区

第六章 市场策略

• 供需差距分析
• 贸易和物流限制
• 价格、成本和利润率趋势
• 市场渗透率
• 消费者分析
• 监管概述

第七章 竞争讯息

• 市场定位
• 市场占有率
• 竞争基准
• 主要企业的策略

第八章：公司简介

• BrainStorm Cell Therapeutics
• Mitsubishi Tanabe Pharma Corporation
• Orphazyme
• AB Science
• MediciNova
• Biogen
• Ionis Pharmaceuticals
• Cytokinetics
• Amylyx Pharmaceuticals
• Apellis Pharmaceuticals
• Anelixis Therapeutics
• Treeway
• Genervon Biopharmaceuticals
• NeuroSense Therapeutics
• QurAlis

第九章 关于我们

Amyotrophic Lateral Sclerosis Market is anticipated to expand from $1.2 billion in 2024 to $2.1 billion by 2034, growing at a CAGR of approximately 5.8%. The Amyotrophic Lateral Sclerosis (ALS) Market encompasses pharmaceuticals, diagnostics, and supportive care aimed at managing ALS, a progressive neurodegenerative disorder. The market is driven by advancements in gene therapy, novel drug development, and increased research funding. Rising awareness and improved diagnostic techniques are propelling demand for innovative treatments. Strategic collaborations and regulatory support further enhance market growth, focusing on extending patient lifespans and improving quality of life.

The Amyotrophic Lateral Sclerosis (ALS) Market is experiencing dynamic growth, propelled by advancements in therapeutic options and diagnostic innovations. The therapeutics segment is the top performer, with disease-modifying therapies and symptomatic treatments leading the charge. Innovative drug formulations and novel therapeutic classes are driving this segment's expansion. The diagnostics segment follows as the second highest performer, with significant advancements in biomarker technologies and genetic testing. These innovations are enhancing early diagnosis and personalized treatment approaches. Research and development activities are intensifying, focusing on neuroprotective agents and regenerative medicine. Emerging biotechnologies and gene therapies are capturing attention, promising to revolutionize ALS treatment paradigms. The integration of artificial intelligence in drug discovery and patient management is further augmenting growth prospects. Collaborations between pharmaceutical companies and research institutions are fostering innovation, accelerating the development of effective solutions. The increasing awareness and advocacy for ALS are also contributing to heightened demand for advanced healthcare solutions.

Market Snapshot:

The Amyotrophic Lateral Sclerosis (ALS) market is witnessing dynamic shifts with significant market share held by leading pharmaceutical companies. Pricing strategies are evolving in response to competitive pressures and patient needs, with innovative pricing models emerging. New product launches are invigorating the market, driven by advancements in biotechnology and a deeper understanding of disease mechanisms. These developments are enhancing treatment options and improving patient outcomes, fostering a competitive landscape. Competition benchmarking reveals a robust rivalry among key players, with strategic partnerships and collaborations shaping the market dynamics. Regulatory influences are pivotal, as agencies in North America and Europe impose stringent guidelines, impacting market entry and expansion strategies. The ALS market is characterized by high R&D investments, focusing on novel therapeutics and personalized medicine. The landscape is further complicated by patent expirations and generic drug entries, which are expected to alter the competitive equilibrium and drive market evolution.

Geographical Overview:

The Amyotrophic Lateral Sclerosis (ALS) market is witnessing varied growth patterns across different regions. North America remains at the forefront, driven by advanced healthcare infrastructure and significant research investments. The presence of leading pharmaceutical companies and robust funding for ALS research further bolster market expansion. Europe follows, with increased awareness and government initiatives supporting ALS treatment advancements. Asia Pacific is emerging as a promising growth pocket, propelled by rising healthcare expenditure and expanding patient awareness. Countries like China and Japan are at the helm, investing heavily in research and development. Meanwhile, Latin America and the Middle East & Africa are gradually gaining momentum. These regions are recognizing the need for improved healthcare frameworks and are beginning to channel resources towards ALS treatment and research. Brazil and South Africa are notable emerging players, showing potential for substantial market growth in the coming years.

Key Trends and Drivers:

The Amyotrophic Lateral Sclerosis (ALS) market is evolving, driven by advancements in research and therapeutic development. Increased funding for neurological research is propelling the discovery of innovative treatment modalities. New drug approvals and clinical trials are expanding therapeutic options, addressing unmet medical needs in ALS care. The rise of personalized medicine is a key trend, with genetic testing enabling targeted therapies tailored to individual patient profiles. This approach enhances treatment efficacy and patient outcomes. Collaborations between pharmaceutical companies and research institutions are accelerating the pace of innovation. Digital health technologies, including telemedicine and remote monitoring, are transforming patient management, improving accessibility to care. These technologies facilitate real-time data collection, enhancing disease tracking and intervention strategies. Regulatory support and incentives for orphan drug development are fostering a conducive environment for market growth. The ALS market is poised for expansion as stakeholders capitalize on these trends, driving progress in diagnosis, treatment, and patient care.

Restraints and Challenges:

The Amyotrophic Lateral Sclerosis (ALS) market encounters several substantial restraints and challenges. A significant restraint is the high cost of drug development and clinical trials. This financial burden limits the entry of new players and slows the pace of innovation. Additionally, the rarity of ALS results in a limited patient pool for clinical studies, which complicates the recruitment process and extends timelines. Another challenge is the lack of definitive diagnostic tests. This results in delayed diagnosis and treatment initiation, affecting patient outcomes. The complexity of ALS pathology also hinders the development of effective therapies. Researchers face difficulties in understanding the disease's underlying mechanisms. Furthermore, regulatory hurdles and stringent approval processes for new treatments can delay market entry. There is also a significant need for increased awareness and education among healthcare professionals and the public. This gap in knowledge can impede early diagnosis and intervention, affecting overall market growth.

Key Players:

BrainStorm Cell Therapeutics, Mitsubishi Tanabe Pharma Corporation, Orphazyme, AB Science, MediciNova, Biogen, Ionis Pharmaceuticals, Cytokinetics, Amylyx Pharmaceuticals, Apellis Pharmaceuticals, Anelixis Therapeutics, Treeway, Genervon Biopharmaceuticals, NeuroSense Therapeutics, QurAlis

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Component
• 2.6 Key Market Highlights by Application
• 2.7 Key Market Highlights by Device
• 2.8 Key Market Highlights by Process
• 2.9 Key Market Highlights by End User

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Sporadic ALS
  • 4.1.2 Familial ALS
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Riluzole
  • 4.2.2 Edaravone
  • 4.2.3 Tirasemtiv
  • 4.2.4 Nuedexta
  • 4.2.5 Masitinib
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Patient Support Services
  • 4.3.2 Consultation Services
  • 4.3.3 Clinical Trial Services
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Biotechnology
  • 4.4.2 Pharmacogenomics
  • 4.4.3 Gene Therapy
  • 4.4.4 Stem Cell Therapy
• 4.5 Market Size & Forecast by Component (2020-2035)
  • 4.5.1 Active Pharmaceutical Ingredients
  • 4.5.2 Excipients
• 4.6 Market Size & Forecast by Application (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Ambulatory Surgical Centers
  • 4.6.3 Research Institutes
• 4.7 Market Size & Forecast by Device (2020-2035)
  • 4.7.1 Non-Invasive Ventilation
  • 4.7.2 Percutaneous Endoscopic Gastrostomy
• 4.8 Market Size & Forecast by Process (2020-2035)
  • 4.8.1 Drug Development
  • 4.8.2 Clinical Trials
  • 4.8.3 Regulatory Approval
  • 4.8.4 Commercialization
• 4.9 Market Size & Forecast by End User (2020-2035)
  • 4.9.1 Healthcare Providers
  • 4.9.2 Patients
  • 4.9.3 Pharmaceutical Companies

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Component
    • 5.2.1.6 Application
    • 5.2.1.7 Device
    • 5.2.1.8 Process
    • 5.2.1.9 End User
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Component
    • 5.2.2.6 Application
    • 5.2.2.7 Device
    • 5.2.2.8 Process
    • 5.2.2.9 End User
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Component
    • 5.2.3.6 Application
    • 5.2.3.7 Device
    • 5.2.3.8 Process
    • 5.2.3.9 End User
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Component
    • 5.3.1.6 Application
    • 5.3.1.7 Device
    • 5.3.1.8 Process
    • 5.3.1.9 End User
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Component
    • 5.3.2.6 Application
    • 5.3.2.7 Device
    • 5.3.2.8 Process
    • 5.3.2.9 End User
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Component
    • 5.3.3.6 Application
    • 5.3.3.7 Device
    • 5.3.3.8 Process
    • 5.3.3.9 End User
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Component
    • 5.4.1.6 Application
    • 5.4.1.7 Device
    • 5.4.1.8 Process
    • 5.4.1.9 End User
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Component
    • 5.4.2.6 Application
    • 5.4.2.7 Device
    • 5.4.2.8 Process
    • 5.4.2.9 End User
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Component
    • 5.4.3.6 Application
    • 5.4.3.7 Device
    • 5.4.3.8 Process
    • 5.4.3.9 End User
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Component
    • 5.4.4.6 Application
    • 5.4.4.7 Device
    • 5.4.4.8 Process
    • 5.4.4.9 End User
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Component
    • 5.4.5.6 Application
    • 5.4.5.7 Device
    • 5.4.5.8 Process
    • 5.4.5.9 End User
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Component
    • 5.4.6.6 Application
    • 5.4.6.7 Device
    • 5.4.6.8 Process
    • 5.4.6.9 End User
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Component
    • 5.4.7.6 Application
    • 5.4.7.7 Device
    • 5.4.7.8 Process
    • 5.4.7.9 End User
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Component
    • 5.5.1.6 Application
    • 5.5.1.7 Device
    • 5.5.1.8 Process
    • 5.5.1.9 End User
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Component
    • 5.5.2.6 Application
    • 5.5.2.7 Device
    • 5.5.2.8 Process
    • 5.5.2.9 End User
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Component
    • 5.5.3.6 Application
    • 5.5.3.7 Device
    • 5.5.3.8 Process
    • 5.5.3.9 End User
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Component
    • 5.5.4.6 Application
    • 5.5.4.7 Device
    • 5.5.4.8 Process
    • 5.5.4.9 End User
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Component
    • 5.5.5.6 Application
    • 5.5.5.7 Device
    • 5.5.5.8 Process
    • 5.5.5.9 End User
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Component
    • 5.5.6.6 Application
    • 5.5.6.7 Device
    • 5.5.6.8 Process
    • 5.5.6.9 End User
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Component
    • 5.6.1.6 Application
    • 5.6.1.7 Device
    • 5.6.1.8 Process
    • 5.6.1.9 End User
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Component
    • 5.6.2.6 Application
    • 5.6.2.7 Device
    • 5.6.2.8 Process
    • 5.6.2.9 End User
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Component
    • 5.6.3.6 Application
    • 5.6.3.7 Device
    • 5.6.3.8 Process
    • 5.6.3.9 End User
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Component
    • 5.6.4.6 Application
    • 5.6.4.7 Device
    • 5.6.4.8 Process
    • 5.6.4.9 End User
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Component
    • 5.6.5.6 Application
    • 5.6.5.7 Device
    • 5.6.5.8 Process
    • 5.6.5.9 End User

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 BrainStorm Cell Therapeutics
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Mitsubishi Tanabe Pharma Corporation
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Orphazyme
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 AB Science
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 MediciNova
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Biogen
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Ionis Pharmaceuticals
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Cytokinetics
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Amylyx Pharmaceuticals
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Apellis Pharmaceuticals
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Anelixis Therapeutics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Treeway
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Genervon Biopharmaceuticals
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 NeuroSense Therapeutics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 QurAlis
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us